Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Overdenture Treatment · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| treatment modalities changed for comparison | ACTIVE_COMPARATOR | All subjects experienced all treatment modalities being studied. |
| Name | Type | Description |
|---|---|---|
| Implant Overdenture Treatment | PROCEDURE | All overdenture treatment modalities were provided to each subject using a crossover design. |
Inclusion: * Adult patient; * Male or female; * At least one year of previous conventional complete denture treatment history; * Willing to accept the conditions of the study and informed consent freely given; * Ability to participate for 6 years; * Able to understand and respond to self-reporting ...
Overdenture Treatment is used for dental implantation, specifically for mandibular implant overdentures. It is an investigational therapy being developed by Envista Holdings Corporation (NYSE: NVST) and is currently in Phase 2 clinical development.
Overdenture Treatment is being developed by Envista Holdings Corporation, which trades on the New York Stock Exchange under the ticker NVST. The company is conducting clinical research on this dental implantation therapy.
Overdenture Treatment is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. One Phase 2 clinical trial has been completed for this dental implantation treatment.
Overdenture Treatment has one completed clinical trial, NCT00066014, titled 'Clinical Investigation of Mandibular Implant Overdenture.' This Phase 2 study enrolled 30 participants in the United States and was active-controlled, with a minimum age of 21 years.
Overdenture Treatment is not FDA approved. It is an investigational therapy currently in Phase 2 clinical development. A Phase 2 trial has been completed, but the treatment remains under investigation for dental implantation.